Table 1 Demographic data of the study subjects.
From: Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis
All | Mepolizumab | Benralizumab | p | |
|---|---|---|---|---|
n (%) | 29 (100) | 20 (69) | 9 (31) | |
Age, years | 63 (53–70) | 64 (57–72) | 61 (48–67) | 0.32 |
Female, n (%) | 22 (76) | 17 (85) | 5 (56) | 0.16 |
Asthma, n (%) | 29 (100) | 20 (100) | 9 (100) | – |
Age of asthma onset (years) | 36 (10–49) | 45 (24–56) | 11 (8–36) | 0.04 |
Age of ABPA onset (years) | 56 (49–66) | 59 (50–66) | 52 (46–64) | 0.44 |
Laboratory data at diagnosis | ||||
Peripheral blood eosinophil counts (/µL) | 1495 (977–2430) | 1823 (1031–3346) | 1166 (830–1525) | 0.006 |
Serum IgE levels (IU/mL) | 1066 (554–3187) | 1033 (512–2718) | 2984 (554–11,028) | 0.15 |
Specific IgE or immediate skin reaction to A. fumigatus, n (%) | 29 (100) | 20 (100) | 9 (100) | – |
Precipitin to A. fumigatus, n (%) | 18 (62) | 12 (60) | 6 (67) | 1.00 |
Fungal culture, n (%) | 12 (41) | 9 (45) | 3 (33) | 0.69 |
Fungal hyphae in mucus plugs, n (%) | 7 (24) | 6 (30) | 1 (11) | 0.38 |
Thoracic CT | ||||
Central bronchiectasis, n (%) | 26 (90) | 18 (90) | 8 (89) | 1.00 |
Mucus plugs, n (%) | 25 (86) | 19 (95) | 6 (67) | 0.07 |
High attenuation mucus, n (%) | 15 (52) | 12 (60) | 3 (33) | 0.22 |
Laboratory data at anti-IL-5/IL-5Rα mAb treatment | ||||
Peripheral blood eosinophil counts (/µL) | 831 (198–1890) | 916 (320–2777) | 245 (87–1305) | 0.11 |
Serum IgE levels (IU/mL) | 888 (193–1798) | 603 (177–1021) | 1758 (315–9595) | 0.05 |
Lung function | ||||
FEV1/FVC (%) | 71 (60–78) | 71 (62–79) | 63 (43–78) | 0.36 |
FEV1, % predicted | 89 (56–101) | 90 (64–109) | 60 (47–101) | 0.35 |
Thoracic CT at anti-IL-5/IL-5Rα mAb treatment | ||||
Mucus plugs, n (%) | 22 (76) | 17 (85) | 5 (56) | 0.15 |
Therapy at anti-IL-5/IL-5Rα mAb treatment | ||||
Oral corticosteroids, n (%) | 15 (52) | 9 (45) | 6 (67) | 0.42 |
Dose of oral corticosteroids, mg prednisolone/day | 5 (4–20) | 5 (3.3–8.8) | 15 (4–30) | 0.18 |
Dose of inhaled corticosteroids, μg budesonide/day | 800 (570–1600) | 800 (425–1280) | 1000 (800–1600) | 0.18 |
Antifungal agents, n (%) | 10 (35) | 6 (30) | 4 (44) | 0.67 |
Omalizumab, n (%) | 7 (24) | 5 (25) | 2 (22) | 0.63 |
